Home / Drugs / nivolumab and relatlimab-rmbw

nivolumab and relatlimab-rmbw

FDA Drug Profile — OPDUALAG

Drug Details

Generic Name
nivolumab and relatlimab-rmbw
Brand Names
OPDUALAG
Application Number
BLA761234
Sponsor
E.R. Squibb & Sons, L.L.C.
NDC Codes
1
Dosage Forms
INJECTION
Routes
INTRAVENOUS
Active Ingredients
NIVOLUMAB, RELATLIMAB

Indications and Usage

1 INDICATIONS AND USAGE OPDUALAG™ is indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. OPDUALAG is a combination of nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody, indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. (1)